Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vanda Pharmaceuticals has said that a study conducted in the schizophrenia patients revealed that a genetic variation in the Ciliary Neurotrophic Factor gene or CNTF may affect response to antipsychotic treatment.
Subscribe to our email newsletter
The study has included patients with acute symptoms of schizophrenia who were treated either with Fiapta (iloperidone), a novel atypical antipsychotic agent or placebo. Patients were also studied for a genetic variation in the CNTF gene. About 75% of the population carries two intact copies of the CNTF protein while 25% carry one or two truncated copies of the protein.
In the patient population carrying both intact copies of CNTF (representing 75% of the population), Fiapta treatment was significantly better than placebo in symptom improvement. In patients carrying at least one truncated copy of the CNTF protein, placebo and Fiapta treated patients had a significant improvement from baseline indicating an enhanced placebo response among this group of patients.